4D Molecular Therapeutics, Inc. Common Stock (FDMT) is a publicly traded Healthcare sector company. As of September 4, 2026, FDMT trades at $14.39 with a market cap of $825.35M and a P/E ratio of -5.54. FDMT moved -1.67% today. Year to date, FDMT is +100.82%; over the trailing twelve months it is +122.39%. Its 52-week range spans $2.24 to $16.93. Analyst consensus is strong buy with an average price target of $32.80. Rallies surfaces FDMT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks hedge fund and 13F ownership for FDMT, including fund holders, share counts, and position changes when data is available.
| Metric | Value |
|---|---|
| Price | $14.39 |
| Market Cap | $825.35M |
| P/E Ratio | -5.54 |
| EPS | $-2.63 |
| Dividend Yield | 0.00% |
| 52-Week High | $16.93 |
| 52-Week Low | $2.24 |
| Volume | 455.79K |
| Avg Volume | 0 |
| Revenue (TTM) | $92.01M |
| Net Income | $-179.18M |
| Gross Margin | 0.00% |
8 analysts cover FDMT: 0 strong buy, 6 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $32.80.